Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: Results of APeX-2 through 48 weeks (part 2)

Authors

H James Wedner, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Allergy and Clinical Immunology: In Practice

Publication Date

6-1-2021

Volume

9

Issue

6

First Page

2305

Last Page

2314.e4

Document Type

Open Access Publication

DOI

10.1016/j.jaip.2021.03.057

Rights and Permissions

Wedner HJ, Aygören-Pürsün E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). J Allergy Clin Immunol Pract. 2021 Jun;9(6):2305-2314.e4. doi: 10.1016/j.jaip.2021.03.057. Copyright 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Wedner, H James and et al., "Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: Results of APeX-2 through 48 weeks (part 2)." Journal of Allergy and Clinical Immunology: In Practice. 9, 6. 2305 - 2314.e4. (2021).
https://digitalcommons.wustl.edu/oa_4/879